At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
Brexpiprazole 1mg to 4mgdrug
Likely dose
Brexpiprazole 1mg to 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted May 16, 2013·Updated Feb 4, 2016
In Brief
A Phase 1 clinical trial evaluating Brexpiprazole 1mg to 4mg for Schizophrenia. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to determine how low and high does of brexpiprazole binds to certain receptors in the brain. This will be determined by PET scans taken pre-dose and post-dose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2013
Enrollment StartSep 2013
Primary CompletionJul 2014
Study CompletionAug 2014
TodayJul 2026
First PostedMay 16, 2013
Enrollment StartSep 1, 2013
Primary CompletionJul 1, 2014
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.1 years ago
Interventions
Brexpiprazole 1mg to 4mgdrug